Abstract
ADVERTISEMENT RETURN TO ISSUEPREVPatent HighlightNEXTUbiquitin-Specific Inhibitors for the Treatment of Cancers, Autoimmune, and Infectious DiseasesRobert B. Kargbo*View Author Information Usona Institute, 277 Granada Drive, San Luis Obispo, California 93401-7337, United States*E-mail: [email protected]Cite this: ACS Med. Chem. Lett. 2017, 8, 12, 1211–1212Publication Date (Web):November 9, 2017Publication History Received28 October 2017Published online9 November 2017Published inissue 14 December 2017https://doi.org/10.1021/acsmedchemlett.7b00449Copyright © 2017 American Chemical SocietyRIGHTS & PERMISSIONSArticle Views1368Altmetric-Citations3LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InReddit PDF (364 KB) Get e-AlertsSUBJECTS:Assays,Cancer,Infectious diseases,Inflammation,Peptides and proteins Get e-Alerts
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
